Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.
Martin Kaiser(Royal Marsden NHS Foundation Trust), Matthew Jenner(University Hospital Southampton NHS Foundation Trust), Gordon Cook(University of Leeds), Christina Messiou(Institute of Cancer Research), Mark T. Drayson(Institute of Immunology), Guy Pratt(University Hospitals Birmingham NHS Foundation Trust), Anand Lokare(University Hospitals Coventry and Warwickshire NHS Trust), Roger G. Owen(Leeds Teaching Hospitals NHS Trust), Kristian M. Bowles(University of East Anglia), Katrina Walker(University of Leeds), Emma Ingleson(University of Leeds), Sadie Roberts(University of Leeds), Andrew Hall(University of Leeds), Graham Jackson(Newcastle College), Ruth de Tute(Leeds Teaching Hospitals NHS Trust), Sarah Brown(University of Leeds), Mamta Garg(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo)
Cited by 17
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial
|The Lancet|2010|640
Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2008|605